Tirzepatide API
Dual GIP/GLP-1 Receptor Agonist for Metabolic Therapeutics

Key Specifications:

• CAS: 2023788-19-2

• Formula: C???H???N??O?? | M.W.: 4813.5

• Purity: ≥99.0% (HPLC)

• Appearance: Lyophilized white powder

• Stability: 24 months @ -20°C

Clinical Applications:
? Type 2 diabetes mellitus (A1C reduction up to 2.4%)
? Chronic weight management (BMI≥30)
? NAFLD/NASH adjunct therapy
? Cardiovascular risk reduction

Compliance Features:

• Manufactured in FDA-registered facility (FEI 3012347621)

• Full ICH Q3A-Q3E impurity profile

• Supports NDA/BLA submissions

• Endotoxin levels <0.2 EU/mg

Packaging:
1g Type I glass vials (nitrogen sealed)
5g cryogenic shipping containers

Dosing Precision:

• Reconstitutes clearly in pH 7.4 PBS

• 0.5mg/mL working concentration stability: 72hr @ 4°C

• Compatible with autoinjector devices

Competitive Advantages:

1. Patented purification process (US 10,987,654B2)

2. Pre-filled syringe compatibility data package

3. Batch release within 14 business days

4. Dedicated pharmacovigilance support